Capital Fund Management (CFM)
ADPT icon

Capital Fund Management (CFM)’s Adaptive Biotechnologies ADPT Stock Holding History

Capital Fund Management (CFM)’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Buy
85,062
+50,589
+147% +$775K 0.01% 1481
2026
Q1 		$478K Buy
+34,473
New +$549K ﹤0.01% 1887

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital Fund Management (CFM)'s ADPT Position: Q2 2026 in Review

Capital Fund Management (CFM) increased its Adaptive Biotechnologies (ADPT) stake by 147% in Q2 2026, buying an estimated $775K and bringing the position to 85,062 shares worth $1.82M. The position accounts for 0.01% of the portfolio, ranked #1481.

Capital Fund Management (CFM) first reported a position in ADPT in Q1 2026 and has held it in 2 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Capital Fund Management (CFM) held 85,062 shares of Adaptive Biotechnologies worth $1.82M as of Q2 2026.
  • Capital Fund Management (CFM) bought 50,589 Adaptive Biotechnologies shares in Q2 2026, an estimated $775K.
  • Adaptive Biotechnologies made up 0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1481 holding.
  • Capital Fund Management (CFM) first reported a position in Adaptive Biotechnologies in Q1 2026 and has held it in 2 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.